STOCK TITAN

Glucotrack expects Q3 net loss of about $29M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

Glucotrack, Inc. (GCTK) notified regulators that it could not file its Form 10-Q for the quarter ended September 30, 2026, within the prescribed time and expects to file within the five-calendar-day extension under Rule 12b-25. The delay primarily concerns accounting analyses and fair-value valuations for derivative liabilities and embedded derivative features in financing instruments. Management is working with valuation specialists and accounting advisers, and additional time is needed for its review and the independent auditor’s interim review.

Glucotrack anticipates operating expenses of approximately $17.2 million, versus approximately $12.6 million in the corresponding 2025 period, and net financing-related expenses of approximately $11.8 million, versus approximately $3.1 million. It anticipates net loss increasing by approximately $13.3 million to $29.0 million. The company attributes the additional expenses to the quarter’s merger with Lokahi and financing transactions. It does not currently expect the delay to result in a material change to previously announced financial information, though the statements remain subject to completion and review.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Net loss: Glucotrack anticipates an increase of approximately $13.3 million to $29.0 million for the quarter ended September 30, 2026.
Filing extension 5 calendar days Glucotrack expects to file its Form 10-Q within the Rule 12b-25 extension period.
Operating expenses Approximately $12.6 million to approximately $17.2 million Corresponding 2025 period to quarter ended September 30, 2026; anticipated increase of approximately $4.6 million.
Net financing-related expenses Approximately $3.1 million to approximately $11.8 million Corresponding 2025 period to quarter ended September 30, 2026; anticipated increase of approximately $8.7 million.
Net loss Approximately $29.0 million; increase of approximately $13.3 million Anticipated for the quarter ended September 30, 2026, compared with the corresponding 2025 period.
derivative liabilities financial
"accounting analyses ... associated with derivative liabilities"
Derivative liabilities are obligations a company records when it owes money under financial contracts whose value depends on something else, like interest rates, stock prices, or currencies. Think of them as bets or insurance policies that can create future cash payments; they matter to investors because they can cause sudden changes in a company’s reported debt, profits and cash flow and reveal exposure to market risks that could affect valuation.
embedded derivative features financial
"embedded derivative features contained in certain financing instruments"
ASC 815, Derivatives and Hedging technical
"required under ASC 815, Derivatives and Hedging"
ASC 820, Fair Value Measurement technical
"and ASC 820, Fair Value Measurement"
fair value measurements financial
"complete the fair value measurements and related accounting analyses"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why was GCTK’s September 2026 quarterly report delayed?

Glucotrack says it needs additional time to complete accounting analyses and fair-value valuations for derivative liabilities and embedded derivative features in financing instruments. The work involves ASC 815, Derivatives and Hedging, and ASC 820, Fair Value Measurement, as well as management review and the independent auditor’s interim review.

When does GCTK expect to file its delayed 10-Q?

Glucotrack expects to file within the five-calendar-day extension provided by Rule 12b-25.

What financial changes does GCTK anticipate for the quarter ended September 30, 2026?

Glucotrack anticipates operating expenses of approximately $17.2 million, compared with approximately $12.6 million, and net financing-related expenses of approximately $11.8 million, compared with approximately $3.1 million, in the corresponding 2025 period. It anticipates net loss increasing by approximately $13.3 million to $29.0 million and attributes additional expenses to the merger with Lokahi and financing transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES OMB APPROVAL
SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058
Washington, D.C. 20549 Expires: September 30, 2028 Estimated average burden hours per response ...............2.50
  SEC FILE NUMBER
FORM 12b-25 001-41141
  CUSIP NUMBER
NOTIFICATION OF LATE FILING 45824Q88

 

(Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K  
  ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
  For Period Ended: September 30, 2026         

 

  ☐ Transition Report on Form 10-K
  ☐ Transition Report on Form 20-F
  ☐ Transition Report on Form 11-K
  ☐ Transition Report on Form 10-Q
    For the Transition Period Ended: _______________________

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this Fo shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 

 

PART I — REGISTRANT INFORMATION

 

Glucotrack, Inc.

 

Full Name of Registrant

 

 

 

Former Name if Applicable

 

301 Rte. 17 North, Ste. 800

 

Address of Principal Executive Office (Street and Number)

 

Rutherford, NJ, 07970

 

City, State and Zip Code

 

SEC 1344 (01-19) Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

 

Board of Governors of the Federal Reserve System          OMB Number 7100-0091           Approval expires February 28, 2027

 

 

 

 
 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

  (a) The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;
     
☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The Company was unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 within the prescribed time period without unreasonable effort or expense. The delay primarily relates to the completion of accounting analyses, valuation procedures, and financial statement disclosures associated with derivative liabilities and embedded derivative features contained in certain financing instruments issued by the Company.

 

Management is working with external valuation specialists and accounting advisors to complete the fair value measurements and related accounting analyses required under ASC 815, Derivatives and Hedging, and ASC 820, Fair Value Measurement. The valuation process requires significant judgment regarding volatility assumptions, probability-weighted outcomes, expected term assumptions, market inputs, and other factors relevant to the determination of fair value.

 

Additional time is required to complete these analyses, finalize the accounting treatment, complete management review procedures, and allow the Company’s independent registered public accounting firm sufficient time to complete its review of the Company’s interim financial statements and related disclosures.

 

The Company expects to file its Form 10-Q within the five-calendar-day extension period provided by Rule 12b-25. The Company does not currently expect that the delay will result in any material change to previously announced financial information, although its financial statements remain subject to completion and review.

 

 
 

 

PART IV — OTHER INFORMATION

 

(1)Name and telephone number of person to contact in regard to this notification

 

Erik Emerson   201   842-7715
(Name)   (Area Code)   (Telephone Number)

 

(2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). X Yes ☐ No

 

(3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
   
  ☒ Yes ☐ No                                     

 

If so, the explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made follows:

 

The merger with Lokahi and the financing transactions occurred during the quarter ended September 30, 2026 resulted in additional operating and financing expenses from the corresponding period in 2025. We anticipate operating expenses increasing by approximately $4.6 million from approximately $12.6 million to approximately $17.2 million. We also anticipate net financing related expenses increasing by approximately $8.7 million from approximately from approximately $3.1 million to approximately $11.8 million. As a result, we anticipate that the net loss increasing approximately $13.3 million to $29.0 million.

 

Forward looking statements

 

This Notification of Late Filing contains forward-looking statements, including statements regarding the Company’s efforts to complete the accounting analysis and valuation of derivative liabilities, finalize its financial statements, and file its Quarterly Report on Form 10-Q within the extension period provided under Rule 12b-25. Actual results may differ materially from those expressed or implied by these forward-looking statements due to risks and uncertainties, including the outcome of the Company’s valuation procedures, ongoing review by management and auditors, the identification of additional accounting issues, and other factors beyond the Company’s control. The Company undertakes no obligation to update any forward-looking statements contained herein except as required by law.

 

 
 

 

GLUCOTRACK, INC.

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date November 16, 2026 By /s/ Erik Emerson
    Erik Emerson, CEO

 

 

 

Keep reading